Researchers at the Keck School of Medicine of USC and the Cleveland Clinic Florida have published studies of a protein implicated in both COVID-19 and multiple types of cancer, and a new drug that interferes with its effects.
Advanced treatment helps a Marine power through a life-threatening disease. Cheering him on are an optimistic oncologist, a close personal advocate and 50,000 fans.
A new class of small molecule drugs, now in phase 1 clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and spread of the deadly cancer.
A USC-led team of researchers finds remarkable results with the blood test in a small group of patients.
USC cancer researcher Min Yu counts on a team that shares her excitement about scientific ideas.
A common manufactured substance may elevate risk of liver cancer, Keck School of Medicine of USC researchers find.
Everyday stressors, traumatic events, job strain and discrimination prematurely weaken the body’s mix of immune cells, potentially increasing a person’s risk of disease.
The California Institute for Regenerative Medicine awards $5.8 million to researchers in the Jane Ann Nohl Division of Hematology at the Keck School of Medicine of USC.
The new location uses the latest technology and includes an on-site laboratory and pharmacy to provide patients with coordinated, personalized care.
After routine prostate cancer screenings were no longer recommended, the incidence rate of metastatic prostate cancer rose more than 40% in men 45 and older, a Keck Medicine of USC study found.
John Carpten and Peter Kuhn will serve in the research effort aimed at reducing the national cancer death rate by 50% in the next 25 years.
The $18.5 million grant will help researchers at USC Norris Comprehensive Cancer Center close the gap in understanding colorectal cancer in Hispanic patients.
Findings from a new study could point the way to new treatments for blood diseases including cancers such as leukemia and lymphoma.
The USC study also underscored a major problem facing cancer researchers: studying non-representative samples of patient cells.
Work from scientists led by USC’s Oliver Bell and a colleague could counteract the effects of mutated epigenetic regulators, which are known to drive certain types of cancer including lymphoma.
A global clinical trial will assess the new therapy, which combines a monoclonal antibody and anti-cancer medication to deliver targeted doses directly to the tumor cells.
With women’s health in mind, USC experts explain why screenings and yearly preventive visits are essential and who may need additional testing offered.
The USC study’s findings are important because they may predict where a specific cancer may spread in the brain, and may also have implications for how brain tumors grow.
As chair of the presidential board, Carpten will be in a position to guide the nation’s cancer research efforts.
USC research indicates that those most at risk of hepatocellular carcinoma are men ages 60-69, non-Hispanic Blacks, American Indian/Alaskan Natives and residents of high-poverty areas.
USC Viterbi doctoral student researchers have found a new way to enhance the cancer-killing properties of CAR T-cell therapies, which makes them more effective in fighting tumors.
Children genetically predisposed to overproduce lymphocytes in relation to other white blood cells are at higher risk of developing acute lymphoblastic leukemia, according to USC research.
Hispanic and non-Hispanic Black women are more likely to have a post-surgery emergency department visit within 90 days than non-Hispanic white women, a USC study found.
The ABAT enzyme helps cancerous medulloblastoma cells feed and survive, according to a study led by the USC Brain Tumor Center and the Norris Comprehensive Cancer Center.